Other News To Note
• Tivorsan Pharmaceuticals Inc., of Providence, R.I., said the Muscular Dystrophy Association awarded it $1 million to help speed preclinical work needed before filing an investigational new drug application for a recombinant humanized form of biglycan in Duchenne's muscular dystrophy (DMD). Tivorsan's approach looks to treat DMD by up-regulating the utrophin protein and its candidate, TVN-102, previously demonstrated a reduction in muscle damage, muscle degeneration and improved muscle function in a mouse model.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter